IDH2 and neoplasm: Good performance (AUROCC around 0.8) was demonstrated in differentiation of the IDH mutation status using a single descriptor of ASL-nCBF or DSC-nCBV (Figure 3A and B), with the highest AUROCC achieved by the median tumor DSC-nCBV (AUROCC = 0.83).